Loading...

CNSP CNS PHARMACEUTICALS INC US FDA Inspections 8-K Filing

CNS

CNSP

CNS PHARMACEUTICALS INC

(CNSP)

2025 8-K

Show Summary

Summary

Reverse Stock Split

Investor Meetings

Equity Offerings

Public Offering

Clinical Trial Update

Financial Update

Equity Offering

Earnings Report

Clinical Trial Update

Clinical Trial Update

Financial Update

Quantitative Data

Filing Letter with Quantita...

US FDA Inspection

Filing with Quantitative Data

Securities Purchase Agreements

Securities Purchase Agreements

Filing with Quantitative Data

Securities Purchase Agreements

Quantitative Data

Clinical Trial Update

Clinical Trial Update

Update on Berubicin Phase 2...

Public Offering

Update on Drug Candidate

Clinical Trial Update

Clinical Trial Update

Warrant Exercise

Other Special Situation

Management Changes

Clinical Trial Update

Clinical Trial Update

Earnings Reports

External Links:

CNS Pharmaceuticals Inc reported a clinical trial update on October 10, 2023, regarding its drug candidate, which is currently in Phase 2 trials for treating brain cancer. The company highlighted positive preliminary results and plans to continue development.

AI Assistant

CNS PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.